#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3816	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2594	435.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1605	1605	C	549	C,G	467,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6074	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3852	470.6	0	.	n	.	0	T695C	SNP	695	695	T	1229	1229	C	487	C,A	413,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6074	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3852	470.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1871	1871	A	504	A	436	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6074	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3852	470.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2505	2505	C	640	C,G	546,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6074	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3852	470.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3131	3131	T	527	T,G	439,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6074	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3852	470.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2579	2579	A	651	A,C	553,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	642	folP	852	852	100.0	folP.l15.c4.ctg.1	2049	93.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1241	1243	AGC	127;126;127	A,T;G;C	108,1;109;110	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1300	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3762	103.6	1	SNP	p	S91F	0	.	.	271	273	TCC	744	746	TCC	116;116;117	T;C;C	97;99;100	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1300	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3762	103.6	1	SNP	p	D95N	0	.	.	283	285	GAC	756	758	GAC	113;114;114	G;A;C	96;96;96	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1300	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3762	103.6	1	SNP	p	D95G	0	.	.	283	285	GAC	756	758	GAC	113;114;114	G;A;C	96;96;96	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	590	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1672	105.2	1	SNP	p	G45D	1	.	.	133	135	GAC	630	632	GAC	157;156;157	G;A;C	138;132;135	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	182	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1255	40.8	0	.	n	.	0	G15A	SNP	15	15	G	544	544	A	26	A	24	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1330	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3394	117.6	1	SNP	p	D86N	0	.	.	256	258	GAC	827	829	GAC	159;159;160	G;A;C	134;135;140	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1330	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3394	117.6	1	SNP	p	S87I	0	.	.	259	261	AGT	830	832	AGT	161;162;162	A;G;T	132;138;140	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1330	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3394	117.6	1	SNP	p	S87R	0	.	.	259	261	AGT	830	832	AGT	161;162;162	A;G;T	132;138;140	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1330	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3394	117.6	1	SNP	p	S87W	0	.	.	259	261	AGT	830	832	AGT	161;162;162	A;G;T	132;138;140	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1330	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3394	117.6	1	SNP	p	S88P	0	.	.	262	264	TCC	833	835	TCC	161;162;161	T;C,A;C	137;142,1;141	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1084	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3105	104.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1750	1752	GGC	143;142;142	G;G;C	120;120;119	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.47.001	penA.47.001	1	1	27	1028	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2675	114.8	1	SNP	p	A311V	0	.	.	931	933	GCC	1394	1396	GCC	125;123;123	G;C;C	108;107;110	penA.47.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1028	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2675	114.8	1	SNP	p	I312M	1	.	.	934	936	ATG	1397	1399	ATG	122;122;122	A;T,C;G	108;108,1;106	penA.47.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1028	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2675	114.8	1	SNP	p	T316P	0	.	.	946	948	ACC	1409	1411	ACC	123;123;122	A;C;C	103;109;106	penA.47.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1028	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2675	114.8	1	SNP	p	V316T	1	.	.	946	948	ACC	1409	1411	ACC	123;123;122	A;C;C	103;109;106	penA.47.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1028	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2675	114.8	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1910	1912	ACC	143;143;143	A;C;C	118;118;116	penA.47.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1028	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2675	114.8	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1964	1966	GCG	130;131;130	G;C;G	117;117;117	penA.47.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1028	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2675	114.8	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1964	1966	GCG	130;131;130	G;C;G	117;117;117	penA.47.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1028	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2675	114.8	1	SNP	p	G542S	0	.	.	1624	1626	GGC	2087	2089	GGC	142;142;142	G,T;G;C	129,1;128;129	penA.47.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1028	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2675	114.8	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2096	2098	GGC	143;143;143	G;G;C	128;130;133	penA.47.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1028	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2675	114.8	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2114	2116	CCG	143;144;145	C,T;C;G	122,2;127;126	penA.47.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1210	ponA	2397	2397	99.96	ponA.l6.c17.ctg.1	3512	103.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	668	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2235	89.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	816	816	C	127	C,A	107,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.72	porB1a.l6.c4.ctg.1	1537	14.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1275	1277	AAT	13;13;13	A;A;T	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.72	porB1a.l6.c4.ctg.1	1537	14.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1278	1280	AAT	13;13;13	A;A;T	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.72	porB1a.l6.c4.ctg.1	1537	14.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1302	1304	GCA	13;13;13	G;C;A	10;9;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.72	porB1a.l6.c4.ctg.1	1537	14.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1325	1327	GTA	13;13;13	G;T;A	9;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.72	porB1a.l6.c4.ctg.1	1537	14.0	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1331	1333	AAC	13;13;13	A;A;C	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.72	porB1a.l6.c4.ctg.1	1537	14.0	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1335	1339	TGGCG	13;13;13;13;13	T;G;G;C;G	10;10;10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.72	porB1a.l6.c4.ctg.1	1537	14.0	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1341	1343	GCT	13;13;13	G;C;T	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.72	porB1a.l6.c4.ctg.1	1537	14.0	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1401	1403	TTA	7;6;6	T;T;A	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.72	porB1a.l6.c4.ctg.1	1537	14.0	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1446	1448	CAT	6;6;6	C;A;T	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.72	porB1a.l6.c4.ctg.1	1537	14.0	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1449	1451	AGT	6;6;6	A;G;T	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.72	porB1a.l6.c4.ctg.1	1537	14.0	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1458	1460	TAC	6;7;7	T;A;C	5;5;5	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	724	porB1b	1035	1035	98.19	porB1b.l6.c17.ctg.1	2194	95.7	0	.	p	.	0	H39L	NONSYN	115	117	CAT	564	566	CTT	153;153;153	C;T,G;T,G	128;126,1;122,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	724	porB1b	1035	1035	98.19	porB1b.l6.c17.ctg.1	2194	95.7	0	.	p	.	0	E48K	NONSYN	142	144	GAA	591	593	AAA	159;160;158	A,G;A;A,C	129,1;135;130,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	724	porB1b	1035	1035	98.19	porB1b.l6.c17.ctg.1	2194	95.7	0	.	p	.	0	R143G	NONSYN	427	429	AGA	876	878	GGA	133;133;133	G,A;G,A;A	119,1;116,1;117	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	724	porB1b	1035	1035	98.19	porB1b.l6.c17.ctg.1	2194	95.7	0	.	p	.	0	S175T	NONSYN	523	525	TCA	972	974	ACA	125;125;125	A,T;C;A	117,1;115;116	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	724	porB1b	1035	1035	98.19	porB1b.l6.c17.ctg.1	2194	95.7	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1080	1080	T	142	T	122	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	724	porB1b	1035	1035	98.19	porB1b.l6.c17.ctg.1	2194	95.7	1	SNP	p	G120K	0	.	.	358	360	GGT	807	809	GGT	143;144;144	G,A;G,A,T;T,G,A	118,1;120,1,1;117,2,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	724	porB1b	1035	1035	98.19	porB1b.l6.c17.ctg.1	2194	95.7	1	SNP	p	A121N	0	.	.	361	363	GCC	810	812	GCC	144;144;144	G;C,A;C	121;119,1;124	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	724	porB1b	1035	1035	98.19	porB1b.l6.c17.ctg.1	2194	95.7	1	SNP	p	A121D	0	.	.	361	363	GCC	810	812	GCC	144;144;144	G;C,A;C	121;119,1;124	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2442	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5248	139.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2215	2217	AAT	157;156;158	A,C;A;T	135,1;130;131	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	378	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1440	77.9	1	SNP	p	V57M	1	.	.	169	171	ATG	656	658	ATG	134;134;134	A;T;G	112;111;111	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
